You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures
|
|---|---|
| Published in |
Frontiers in Cellular Neuroscience, April 2016
|
| DOI | 10.3389/fncel.2016.00090 |
| Pubmed ID | |
| Authors |
Yehezkel Ben-Ari, Philippe Damier, Eric Lemonnier |
| Abstract |
The diuretic bumetanide failed to treat acute seizures due to hypoxic ischemic encephalopathy (HIE) in newborn babies and was associated with hearing loss (NEMO trial, Pressler et al., 2015). On the other hand, clinical and experimental observations suggest that the diuretic might provide novel therapy for many brain disorders including Autism Spectrum Disorders (ASD), schizophrenia, Rett syndrome, and Parkinson disease. Here, we discuss the differences between the pathophysiology of severe recurrent seizures in the neonates and neurological and psychiatric disorders stressing the uniqueness of severe seizures in newborn in comparison to other disorders. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 50% |
| Switzerland | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 72 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 18% |
| Student > Ph. D. Student | 9 | 13% |
| Researcher | 8 | 11% |
| Student > Doctoral Student | 5 | 7% |
| Student > Bachelor | 5 | 7% |
| Other | 15 | 21% |
| Unknown | 17 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 25 | 35% |
| Medicine and Dentistry | 11 | 15% |
| Agricultural and Biological Sciences | 6 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Psychology | 2 | 3% |
| Other | 6 | 8% |
| Unknown | 20 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2017.
All research outputs
#3,150,337
of 25,654,806 outputs
Outputs from Frontiers in Cellular Neuroscience
#562
of 4,742 outputs
Outputs of similar age
#48,093
of 315,971 outputs
Outputs of similar age from Frontiers in Cellular Neuroscience
#9
of 94 outputs
Altmetric has tracked 25,654,806 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,742 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,971 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 94 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.